La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on improving and preserving human life through the development of novel pharmaceutical products. Riquent®, the company’s leading product in development, treats lupus renal disease, a leading cause of sickness and death in patients with lupus, by preventing or delaying renal flares. Additionally, La Jolla has developed small molecules designed to treat other autoimmune and inflammatory conditions. For further information, visit the Company’s web site at www.ljpc.com.
- 17 years ago
QualityStocks
La Jolla Pharmaceutical Company (NASDAQ: LJPC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Engages IBN for Corporate Communications Expertise
Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) is a junior resource company focused on monetizing high-grade…
-
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research
Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective…
-
ONAR Holding Corp. (ONAR) Is ‘One to Watch’
ONAR is scaling a diversified, AI-driven marketing network addressing multiple high-growth industry verticals. The company…